5.74
price up icon3.42%   0.19
after-market 시간 외 거래: 5.74
loading
전일 마감가:
$5.55
열려 있는:
$5.55
하루 거래량:
411.13K
Relative Volume:
2.13
시가총액:
$84.12M
수익:
-
순이익/손실:
$-64.47M
주가수익비율:
-0.928
EPS:
-6.1852
순현금흐름:
$-52.33M
1주 성능:
+3.05%
1개월 성능:
+4.36%
6개월 성능:
-73.15%
1년 성능:
-75.19%
1일 변동 폭
Value
$5.4972
$6.10
1주일 범위
Value
$5.12
$6.10
52주 변동 폭
Value
$3.1301
$26.05

Jasper Therapeutics Inc Stock (JSPR) Company Profile

Name
명칭
Jasper Therapeutics Inc
Name
전화
(650) 549-1400
Name
주소
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Name
직원
64
Name
트위터
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
JSPR's Discussions on Twitter

JSPR을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
JSPR
Jasper Therapeutics Inc
5.74 84.12M 0 -64.47M -52.33M -6.1852
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-02-13 개시 UBS Buy
2024-12-06 개시 BMO Capital Markets Outperform
2024-09-09 개시 JMP Securities Mkt Outperform
2024-07-08 개시 BTIG Research Buy
2024-06-27 개시 Stifel Buy
2024-05-06 개시 H.C. Wainwright Buy
2024-04-03 개시 Evercore ISI Outperform
2024-03-28 개시 RBC Capital Mkts Outperform
2024-03-18 개시 TD Cowen Outperform
2023-08-11 개시 CapitalOne Overweight
2022-02-28 개시 Cantor Fitzgerald Overweight
2021-11-08 개시 Credit Suisse Outperform
2021-10-21 개시 William Blair Outperform
2021-10-20 개시 BMO Capital Markets Outperform
2021-10-13 개시 Oppenheimer Outperform
모두보기

Jasper Therapeutics Inc 주식(JSPR)의 최신 뉴스

pulisher
Jun 18, 2025

When the Price of (JSPR) Talks, People Listen - news.stocktradersdaily.com

Jun 18, 2025
pulisher
Jun 18, 2025

Draig Therapeutics launches with $140 million - The Pharma Letter

Jun 18, 2025
pulisher
Jun 16, 2025

Solu Therapeutics appoints new COO - The Pharma Letter

Jun 16, 2025
pulisher
Jun 16, 2025

Jasper Therapeutics Reports Positive Phase 1b/2a Study Results - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

Jasper Therapeutics’ SWOT analysis: briquilimab’s potential in CSU market drives stock outlook - Investing.com Nigeria

Jun 16, 2025
pulisher
Jun 16, 2025

Jasper releases new data on briquilimab from SPOTLIGHT trial - The Pharma Letter

Jun 16, 2025
pulisher
Jun 15, 2025

JSPR: Promising Results from Phase 1b/2a Study of Briquilimab | - GuruFocus

Jun 15, 2025
pulisher
Jun 15, 2025

JSPR: Promising Results from Phase 1b/2a Study of Briquilimab | JSPR Stock News - GuruFocus

Jun 15, 2025
pulisher
Jun 14, 2025

Jasper Therapeutics Reports Positive Data from 180mg Cohort - GlobeNewswire

Jun 14, 2025
pulisher
Jun 14, 2025

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria - GlobeNewswire Inc.

Jun 14, 2025
pulisher
Jun 14, 2025

Jasper Therapeutics’ SWOT analysis: briquilimab’s potential in CSU stock scrutinized - Investing.com Canada

Jun 14, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Weighs in on JSPR FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Public market insider buying at Canaccord Genuity Group (CF) - The Globe and Mail

Jun 10, 2025
pulisher
Jun 08, 2025

Wellington Management Group LLP Boosts Stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

Trend Tracker for (JSPR) - news.stocktradersdaily.com

Jun 06, 2025
pulisher
Jun 06, 2025

Is Monster Beverage Stock Outperforming the S&P 500? - The Globe and Mail

Jun 06, 2025
pulisher
Jun 05, 2025

Jane Street Group LLC Sells 2,502 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

Warren Buffett Is Ready to Invest $100 Billion in a Stock That Meets These 3 Criteria - The Globe and Mail

Jun 05, 2025
pulisher
Jun 03, 2025

Jasper Therapeutics Announces Acceptance of Four Abstracts for Presentation at EAACI Congress 2025 - Nasdaq

Jun 03, 2025
pulisher
Jun 03, 2025

Jasper Therapeutics Announces Briquilimab Presentations at - GlobeNewswire

Jun 03, 2025
pulisher
Jun 03, 2025

Breakthrough Clinical Data: Jasper's Briquilimab Shows Promise in Treating Resistant Urticaria Cases - Stock Titan

Jun 03, 2025
pulisher
May 31, 2025

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

May 31, 2025
pulisher
May 29, 2025

Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely - Yahoo Finance

May 29, 2025
pulisher
May 27, 2025

Buy Rating for Jasper Therapeutics: Potential Breakthrough with Briquilimab in CSU Market - TipRanks

May 27, 2025
pulisher
May 27, 2025

Bank of America Corp DE Cuts Stock Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World

May 27, 2025
pulisher
May 26, 2025

Northern Trust Corp Trims Stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World

May 26, 2025
pulisher
May 26, 2025

Market Analysis: May 26th, 2025 - The Globe and Mail

May 26, 2025
pulisher
May 25, 2025

Jasper Therapeutics’ SWOT analysis: briquilimab stock potential in urticaria treatment - Investing.com Canada

May 25, 2025
pulisher
May 25, 2025

Jasper Therapeutics’ SWOT analysis: briquilimab stock potential in urticaria treatment By Investing.com - Investing.com South Africa

May 25, 2025
pulisher
May 21, 2025

Jasper Therapeutics, Inc. (JSPR): Analysts See 914% Upside Potential - Insider Monkey

May 21, 2025
pulisher
May 21, 2025

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Stake Lifted by Deutsche Bank AG - Defense World

May 21, 2025
pulisher
May 20, 2025

Spotify Stock's Rally Still Has Legs To Run Higher - The Globe and Mail

May 20, 2025
pulisher
May 18, 2025

Cantor Fitzgerald Brokers Lower Earnings Estimates for JSPR - Defense World

May 18, 2025
pulisher
May 18, 2025

Oppenheimer Cuts Jasper Therapeutics (NASDAQ:JSPR) Price Target to $65.00 - Defense World

May 18, 2025
pulisher
May 16, 2025

Jasper Therapeutics (JSPR) Price Target Lowered by Oppenheimer | JSPR Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

(JSPR) Trading Report - news.stocktradersdaily.com

May 16, 2025
pulisher
May 16, 2025

CRSPR Stock Could Be Ready to Deliver on Its Massive Promise - The Globe and Mail

May 16, 2025
pulisher
May 16, 2025

William Blair Issues Pessimistic Outlook for JSPR Earnings - Defense World

May 16, 2025
pulisher
May 16, 2025

Q2 EPS Forecast for Jasper Therapeutics Increased by Analyst - Defense World

May 16, 2025
pulisher
May 15, 2025

Oppenheimer Cuts Price Target on Jasper Therapeutics to $65 From $80, Keeps Outperform Rating - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Oppenheimer Adjusts Price Target for Jasper Therapeutics (JSPR) - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Oppenheimer Adjusts Price Target for Jasper Therapeutics (JSPR) | JSPR Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Jasper Therapeutics to Present at Upcoming Investor Conferences - The Manila Times

May 15, 2025
pulisher
May 14, 2025

Jasper Therapeutics to Present at RBC and Jefferies Global Healthcare Conferences on Briquilimab Development - Nasdaq

May 14, 2025
pulisher
May 14, 2025

Jasper Therapeutics Showcases Novel Antibody Therapy at Major Healthcare Conferences This Summer - Stock Titan

May 14, 2025
pulisher
May 14, 2025

UBS Maintains Buy Rating for Jasper Therapeutics (JSPR) Despite Price Target Adjustment | JSPR Stock News - GuruFocus

May 14, 2025
pulisher
May 13, 2025

JSPR Price Target Adjusted by UBS Amidst Upcoming Clinical Updates | JSPR Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Jasper (JSPR) Advances Briquilimab with Promising Trial Results - GuruFocus

May 13, 2025
pulisher
May 13, 2025

UBS Adjusts Price Target on Jasper Therapeutics to $33 From $38, Maintains Buy Rating - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times

May 13, 2025
pulisher
May 13, 2025

Jasper Therapeutics Faces Financial Challenges Amid Rising R&D Costs - TipRanks

May 13, 2025

Jasper Therapeutics Inc (JSPR) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Jasper Therapeutics Inc 주식 (JSPR) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Mahal Jeetinder Singh
Chief Operating Officer
Dec 12 '24
Sale
22.11
900
19,899
25,009
$20.74
price up icon 0.27%
$35.88
price down icon 0.50%
$21.20
price down icon 0.38%
$97.62
price down icon 2.98%
$107.51
price up icon 0.95%
biotechnology ONC
$245.16
price up icon 1.13%
자본화:     |  볼륨(24시간):